Groupe de Recherche et d’Action sur le Foncier

Recent papers from Groupe de Recherche et d’Action sur le Foncier

1. Antibody-mediated functional responses induced by the SchistoShield® schistosomiasis vaccine in disease-naïve and endemic human populationsVaccine · 2026
2. Widespread Variants of the Highly Polymorphic Plasmodium falciparum Vaccine Candidate Antigen MSP2 Across Sub-Saharan AfricaThe Journal of Infectious Diseases · 2026
3. Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine–pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a studyThe Lancet Infectious Diseases · 2026
4. Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trialThe Lancet Infectious Diseases · 2026
5. Fc-fucosylation of Plasmodium falciparum -specific IgG varies with antigen and immunizationThe Journal of Infectious Diseases · 2026
6. Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populationsnpj Vaccines · 2026
7. Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort studyThe Lancet Global Health · 2026
8. African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African childrenNature Communications · 2026
9. IgG and IgM responses to PfEMP1 domains associated with semi-immunity to clinical malaria in Burkinabe children under fiveFrontiers in Immunology · 2026
10. Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshopVaccine · 2026
11. Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV)EClinicalMedicine · 2026
12. Five-Year Experience of the Groupe de Recherche Action en Santé (GRAS) Clinical Laboratory, Burkina Faso, in Participating into an External Proficiency Testing (EPT) ProgrammeDiagnostics · 2025
13. Incidence and antimicrobial resistance of non-typhoidal Salmonella enterica in stool samples from children under five in peri-urban Ouagadougou, Burkina FasoBMC Microbiology · 2025
14. Pharmacokinetics, safety and efficacy of an optimized dose of artemether–lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in neonates and infants of less than 5 kg body weight: a multicentre, open-label, single-arm phase 2/3 study (CALINA)Tropical Medicine and Health · 2025
15. A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina FasoVaccines · 2025
16. Must Epidemiologically Impactful Vector Control Interventions Disrupt Mosquito Population Structure? A Case Study of a Cluster‐Randomised Controlled TrialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2025
17. Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina FasoMalaria Journal · 2025
18. Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.2025
19. Influence of genetic factors of humans, mosquitoes and parasites, on the evolution of Plasmodium falciparum infections, malaria transmission and genetic control methods: a review of the literatureBMC Medical Genomics · 2025
20. OSBPL11 is an African-specific locus associated with 25-hydroxyvitamin D concentrations and cardiometabolic health2025